The Latest Convergence of AI & HPC, the 29th HPC Connection Workshop at ISC22
The 29th HPC Connection Workshop (HPCC) will be held online at 2pm (CEST) on May 30, 2022, at ISC22 with the theme "The Latest Convergence of AI & HPC." World renowned experts and industry leaders will introduce the latest in the convergence of AI and HPC.
Featured speakers include:
- Jean-Marc Denis, Chief Strategy Officer of SiPearl, will describe new paradigms and challenges in Exascale era with the perspective of the key decisions made for Rhea processor architecture and design. Rhea is built on Arm's Neoverse V1 processor architecture, but it also has 29 RISC-V cores deployed as controllers. Rhea is planned to be deployed in an European Exascale supercomputer in 2023.
- Radoslav Danilak, CEO of Tachyum, will provide an overview of the features and benefits of Tachyum Prodigy, the world’s first Universal Processor. With 128 64-bit CPU cores operating at up to 5.7GHz, Prodigy not only handles general-purpose computing, HPC, and AI workloads on a single chip, it does so with a power budget that's 10 times lower than that of traditional hardware and at one-third the cost.
- Wolfgang Gentzsch, President of UberCloud, will summarize UberCloud’s 10 year achievements and present several customer use cases, and elaborate on UberCloud’s fully automated, portable, self-service, and multi-cloud engineering platform.
- Shu Yin, Assistant Professor at ShanghaiTech University, will share how to optimize HPC applications from the perspective of I/O, and will demonstrate best practices and use cases.
- Weizheng Lu, Tech Lead of Public Computing Center at Renmin University of China, will talk about Jax-Quant-Finance, and the High Performance Quantitative Library which brings HPC, Deep Learning, and Financial Mathematics together to accelerate financial problems time-to-resolution on heterogeneous platforms.
- Longxiang Li, Senior HPC engineer at Inspur Information, will detail the building of data-driven scientific workflows by coupling HPC with machine learning methods and introduce Inspur’s recent achievements in the fields of materials science, CFD, and ocean modeling.
|
The 29th HPC Connection Workshop Digital 2pm (CEST) May 30, 2022 Online |
|
Agenda |
|
Rhea Processor: Overall Strategic Directions and Specifications Jean-Marc Denis Chief Strategy Officer (CSO), SiPearl |
|
Tachyum Prodigy, The World’s First Universal Processor Radoslav Danilak CEO, Tachyum |
|
10 Year HPC in the Cloud: From Early Cloud Experiments to a Fully Automated Simulation Multi-Cloud Platform for Complex Engineering Workflows Wolfgang Gentzsch President of UberCloud |
|
Optimize HPC applications from the I/O perspectives Shu Yin Assistant Professor, ShanghaiTech University |
|
Jax-Quant-Finance: Bring HPC, Deep Learning and Financials Mathematics together Weizheng Lu Tech Lead of Public Computing Center, Renmin University of China |
|
Building data-driven scientific workflows with machine learning and HPC applications Longxiang Li Senior HPC engineer, Inspur Information |
Click here to register: http://www.asc-events.net/HPCC/ISC22.php
About HPC Connection Workshop
The HPC Connection Workshop is an international High Performance Computing event organized by the Asia Supercomputer Community and Inspur Information. This event takes place three times a year: during ASC in China, ISC in Germany, and SC in the USA. Top researchers and leading professionals from around the world gather at the workshops to discuss the latest developments and disruptive technologies in AI and supercomputing. Visit ASC's website for highlights and videos of the past events: (http://www.asc-events.org/).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005035/en/
Contact information
Fiona Liu
media@asc-events.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom